Latest Boehringer Ingelheim Corporation Stories
Clinical and pre-clinical data on compounds representing several of the largest diabetes treatment classes will be presented RIDGEFIELD, Conn.
STIOLTO RESPIMAT is the only COPD treatment that includes two proven agents: tiotropium, the active ingredient in SPIRIVA®, and olodaterol RIDGEFIELD, Conn., May 26, 2015 /PRNewswire/ -- Boehringer
New data analyses further examine efficacy and safety across all GOLD categories, as well as COPD patients beginning or already on a maintenance therapy, including inhaled corticosteroids (ICS) DENVER,
Long-term OFEV treatment in the INPULSIS® extension study reinforces the safety and tolerability profile for up to 33 months in patients with IPF RIDGEFIELD, Conn., May 18, 2015 /PRNewswire/
- LUX-Lung 8 Phase III study evaluating the efficacy and safety of afatinib vs.
RIDGEFIELD, Conn., and SACRAMENTO, Calif., May 11, 2015 /PRNewswire/ -- Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern
- 60 percent of surveyed U.S.
RIDGEFIELD, Conn., April 6, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.
- Nearly double the percentage of patients on BI 655066 with clear or almost clear skin (PASI 90) after 12 weeks vs.
-- Data show initial therapy in newly diagnosed NVAF patients diverged from guideline recommendations RIDGEFIELD, Conn., March 16, 2015 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals,
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).